Natural Language Processing for Patient Selection in Phase I or II Oncology Clinical Trials.

Journal: JCO clinical cancer informatics
Published Date: Jun 1, 2021

Abstract

PURPOSE: Early discontinuation affects more than one third of patients enrolled in early-phase oncology clinical trials. Early discontinuation is deleterious both for the patient and for the study, by inflating its duration and associated costs. We aimed at predicting the successful screening and dose-limiting toxicity period completion (SSD) from automatic analysis of consultation reports.

Authors

  • Julie Delorme
    Institut Optique Graduate School, Paris, France.
  • Valentin Charvet
    Gustave Roussy Cancer Campus, Villejuif, France.
  • Muriel Wartelle
    Informatic Team (DTNSI), Gustave Roussy, Villejuif, France.
  • François Lion
    Informatic Team (DTNSI), Gustave Roussy, Villejuif, France.
  • Bruno Thuillier
    Drug Development Department (DITEP), Gustave Roussy, Villejuif, France.
  • Sandrine Mercier
    Drug Development Department (DITEP), Gustave Roussy, Villejuif, France.
  • Jean-Charles Soria
    Drug Development Department (DITEP), Gustave Roussy, Villejuif, France.
  • Mikael Azoulay
    Direction de la Transformation Numérique et des Systèmes d'Information, Gustave Roussy, Université Paris-Saclay, 94805, Villejuif, France.
  • Benjamin Besse
    University Paris-Saclay, Gif-sur-Yvette, France.
  • Christophe Massard
    Gustave Roussy Cancer Campus, Villejuif, France.
  • Antoine Hollebecque
    Gustave Roussy Cancer Campus, Villejuif, France.
  • Loic Verlingue
    Gustave Roussy Cancer Campus, Villejuif, France.

Keywords

External Resources

Popular Topics
Recent Journals